Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Better Buy: Celgene vs. Starbucks

By Mark Reeth and Max Macaluso - Mar 20, 2014 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We've collected the most popular companies among Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better Buy Tournament.

In today's ­first-round matchup of The Motley Fool Better Buy Tournament, Celgene ( CELG ) squares off against Starbucks ( SBUX -0.89% ) in a battle to determine which stock is the better buy now. The 64-company tournament pits two Motley Fool analysts against each other as they make the case for their stocks, with the winner determined by you, the readers.

In the video below, Motley Fool analyst Max Macaluso makes the case for Celgene, a big biotech company, to move to the next round. After doubling in 2013, Celgene has faced a slow start to the year. However, the company's growing portfolio and pipeline make it a biotech to watch over the long term.

Starbucks has never been afraid of change, which is why Motley Fool Consumer Goods Editor Mark Reeth thinks it's one of the best companies on the market. Its mobile app has been a welcome addition to coffee drinkers' morning routines, with 10 million users signed up for the service. Starbucks also has been rapidly expanding overseas to great success: Revenue in the China/Asia-Pacific region was up 25% this past quarter, and that is only expected to grow. Lastly, the company is expanding its retail offerings and breaking into the tea market, which is just icing on the cake.

Watch these analysts square off in the video below and then vote for a winner. Then check out the other companies in the Motley Fool Better Buy Bracket

This year's winning stock?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Cast your vote in the poll below the video!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Starbucks Corporation Stock Quote
Starbucks Corporation
SBUX
$108.66 (-0.89%) $0.98
Celgene Corporation Stock Quote
Celgene Corporation
CELG

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.